Company: INDP
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001493152-25-021759
Chunk: 6

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 1
Chunk 6
---
     6,396,888  
     3,375,590 
  
    Proceeds from exercise of pre-funded warrants 
     154  
     - 
  
    Issuance costs 
     (440,213) 
     (429,516)
  
    Net cash provided by financing activities 
     11,671,629  
     2,946,074 

    Net increase (decrease) in cash and cash equivalents 
     38,886  
     (5,981,367)

    Cash and cash equivalents at beginning of period 
     5,786,753  
     13,362,053 

    Cash and cash equivalents at end of period 
    $5,825,639  
    $7,380,686 

    Noncash investing and financing activities 

    Transaction costs in accounts payable and other current liabilities 
    $-  
    $129,993 
  
    Settlement of convertible promissory notes 
    $6,868,221  
    $- 
  
    Issuance of commitment shares* 
    $109  
    $- 

    *
    Retroactively
    restated for one-for-twenty-eight share consolidation on June 27, 2025.

See
accompanying notes to the unaudited condensed consolidated financial statements

F-4

INDAPTUS
THERAPEUTICS, INC.

Notes
to the unaudited condensed consolidated financial statements

NOTE
1: GENERAL

Indaptus
Therapeutics, Inc. and its wholly-owned subsidiaries, Decoy Biosystems, Inc. and Intec Pharma Ltd., collectively (the “Company”),
is a biotechnology company dedicated to enhancing and expanding curative cancer immunotherapy for patients with unresectable or metastatic
solid tumors and lymphomas, which are responsible for more than 90% of all cancer deaths. The Company is developing a novel, multi-targeted
product that activates both innate and adaptive anti-tumor and anti-viral immune responses.

Risks
and uncertainties

The
Company is subject to a number of risks similar to those of other companies of similar size in its industry, including, but not limited
to, the need for successful development of products, the need for additional capital (or financing) to fund operations (see below), competition
from substitute products and services from larger companies, protection of proprietary technology, patent litigation, and dependence